Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids
Open Access
- 1 August 1999
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 42 (8) , 1601-1608
- https://doi.org/10.1002/1529-0131(199908)42:8<1601::aid-anr6>3.0.co;2-b
Abstract
Objective Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine whose involvement in tumor necrosis factor α (TNFα) synthesis and T cell activation suggests a role in the pathogenesis of rheumatoid arthritis (RA). Antagonism of MIF is associated with marked inhibition of animal models of RA. Uniquely, MIF is inducible by low concentrations of glucocorticoids. We sought to investigate the expression of MIF in RA synovial tissue. Methods MIF was demonstrated in human RA synovium by immunohistochemistry, flow cytometry, enzyme‐linked immunosorbent assay (ELISA), and reverse transcription–polymerase chain reaction (RT‐PCR). Regulation of MIF expression was investigated by treatment of cultured fibroblast‐like synoviocytes (FLS) with interleukin‐1β (IL‐1β), TNFα, or interferon‐γ (IFNγ), and dexamethasone (DEX). Mononuclear cell TNFα release after exposure to FLS‐conditioned medium was measured by ELISA. Results MIF was present in RA synovial lining CD14+ macrophages and FLS. Constitutive MIF messenger RNA (mRNA) expression was demonstrated by RT‐PCR of RNA from unstimulated cultured RA FLS, which also released abundant MIF. Serum, synovial fluid, and FLS intracellular MIF were significantly higher in RA patients than in controls. Synoviocyte MIF was not increased by IL‐1β, TNFα, or IFNγ. In contrast, DEX 10−7M significantly reduced synoviocyte MIF, while DEX 10−10–10−12M induced a significant increase in MIF and MIF mRNA. Peripheral blood mononuclear cell TNFα release was induced by culture in RA FLS‐conditioned medium, and this induction was significantly abrogated by monoclonal anti‐MIF antibody, suggesting that MIF is an upstream regulator of TNFα release. Conclusion These data represent the first demonstration of the cytokine MIF in human autoimmune disease and suggest MIF as a potential therapeutic target in RA.Keywords
This publication has 36 references indexed in Scilit:
- IDENTIFICATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN HUMAN VASCULAR ENOTHELIAL CELLS AND ITS INDUCTION BY LIPOPOLYSACCHARIDECytokine, 1998
- Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?Arthritis & Rheumatism, 1997
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- NITRIC OXIDE PRODUCTION IN CELLS DERIVED FROM THE HUMAN JOINTRheumatology, 1996
- An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction.The Journal of Experimental Medicine, 1996
- Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritisArthritis & Rheumatism, 1995
- Purification, Bioactivity, and Secondary Structure Analysis of Mouse and Human Macrophage Migration Inhibitory Factor (MIF)Biochemistry, 1994
- Cytokines and oncogenes in cellular interactions of rheumatoid arthritisThe International Journal of Cell Cloning, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988